文献类型：期刊文献

英文题名：Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

作者：Zhang, Lin[1];Zhou, Chao[2];Zhang, Songou[3];Chen, Xiaozhen[3];Liu, Jian[4];Xu, Fangming[5];Liang, Wenqing[6]

机构：[1]Zhejiang Univ, Shaoxing Peoples Hosp, Shaoxing Hosp, Dept Pharm,Sch Med, Shaoxing, Peoples R China;[2]Zhoushan Guanghua Hosp, Dept Orthoped, Zhoushan, Peoples R China;[3]Shaoxing Univ, Coll Med, Shaoxing, Peoples R China;[4]Shanghai Oriental Hepatobiliary Hosp, Dept Hepatobiliary Surg, Shanghai, Peoples R China;[5]Zhejiang Chinese Med Univ, Dept Gastroenterol, Zhoushan Hosp Tradit Chinese Med, Zhoushan, Peoples R China;[6]Zhejiang Chinese Med Univ, Med Res Ctr, Zhoushan Hosp Tradit Chinese Med, Zhoushan, Peoples R China

年份：2022

卷号：12

外文期刊名：FRONTIERS IN ONCOLOGY

收录：SCI-EXPANDED(收录号：WOS:000843312300001)、、Scopus(收录号：2-s2.0-85136879101)、WOS

基金：Funding This work was supported by the Project of Shaoxing Medical Key Discipline Construction Plan (2019SZD06 to LZ) and the Project of Health and Family Planning Commission of Zhejiang Province (2021KY1139, and 2018KY831 to LZ), Shaoxing Medical and Health Science and Technology Plan Project (2020A13026 to LZ).

语种：英文

外文关键词：combination therapy; chemotherapy; immune checkpoint inhibitors; tumor microenvironment; cancer treatment

外文摘要：New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into molecular mechanisms and regimens that uplift the efficacy of immunotherapy since only a minority of cancer patients are responsive to immune checkpoint inhibitors (ICIs). Recent findings on combination therapy of chemotherapy and ICIs have shown promising results. This strategy increases tumor recognition and elimination by the host immune system while reducing immunosuppression by the tumor microenvironment. Currently, several preclinical studies are investigating molecular mechanisms that give rise to the immunomodulation by chemotherapeutic agents and exploit them in combination therapy with ICIs in order to achieve a synergistic clinical activity. In this review, we summarize studies that exhibit the capacity of conventional chemotherapeutics to elicit anti-tumor immune responses, thereby facilitating anti-tumor activities of the ICIs. In conclusion, combining chemotherapeutics with ICIs appears to be a promising approach for improving cancer treatment outcomes.